Intravitreal drug therapy for retinal vein occlusion pathophysiological mechanisms and routinely used drugs;Intravitreale Medikamenteneingabe bei retinalem Venenverschluss pathophysiologische Mechanismen und angewandte Substanzen

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 9, 2010, Pages 681-693

  Feltgen, N ^a   Pielen, A ^b   Hansen, L ^b   Bertram, B ^c   Agostini, H ^b   Jaissle, G B ^d   Hoerauf, H ^a   Stahl, A ^b,e  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Augenarztpraxis   (Germany)

^d Universi ts Augenklinik Tbingen   (Germany)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

intravitreal injection; pathology; retina; vitreous

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; APTAMER; ERYTHROPOIETIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

FLUORESCENCE ANGIOGRAPHY; HUMAN; OPHTHALMOSCOPY; PATHOPHYSIOLOGY; PROGNOSIS; RETINA VEIN OCCLUSION; REVIEW; BLOOD FLOW VELOCITY; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HEMODILUTION; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; LONG TERM CARE; METABOLISM; MULTIMODALITY CANCER THERAPY; PAPILLEDEMA; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ARTERY; RETINA VEIN; VASCULAR ENDOTHELIUM;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BLOOD FLOW VELOCITY; CELL DIVISION; COMBINED MODALITY THERAPY; DEXAMETHASONE; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HEMODILUTION; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; LONG-TERM CARE; PAPILLEDEMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL ARTERY; RETINAL VEIN; RETINAL VEIN OCCLUSION; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956903459     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245606     Document Type: Review

References (157)

1. Sedney S. Photocoagulation and retinal vein occlusion. Documenta ophthalmologica 1976 40 1-241
2. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration] Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenrzte Deutschlands zu aktuellen therapeutischen Mglichkeiten bei der neovaskulren altersabhngigen Makuladegeneration. Klin Monbl Augenheilkd 2007 224 559-566
3. Lardenoye C W., Probst K, DeLint P J. et al. Photoreceptor function in eyes with macular edema. Investigative ophthalmology & visual science 2000 41 4048-4053
4. Wu L, Martinez-Castellanos M A., Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2008 246 81-87
5. Stahl A, Feltgen N, Fuchs A et al. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Documenta ophthalmologica 2009 118 81-88
6. Spaide R F., Chang L K., Klancnik J M. et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. American journal of ophthalmology 2009 147 298-306
7. Gregori N Z., Gaitan J, Rosenfeld P J. et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 2008 28 1325-1337
8. Prager F, Michels S, Kriechbaum K et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. The British journal of ophthalmology 2009 93 452-456
9. Jaissle G, Szurman P, Feltgen N et al. Predictive Factors for Functional Improvement after Intravitreal Bevacizumab Therapy for Macular Edema due to Branch Retinal Vein Occlusion. Joint Congress of the Asia Pacific Academy of Ophthalmology and the American Academy of Ophthalmology Bali, Indonesia 2010
10. Wu L, Arevalo J F., Berrocal M H. et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009 29 1396-1403
11. Stahl A, Struebin I, Hansen L L. et al. Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. European journal of ophthalmology 2010 20 180-185
12. Cugati S, Cikamatana L, Wang J J. et al. Five-year incidence and progression of vascular retinopathy in persons without diabetes: the Blue Mountains Eye Study. Eye 2006 20 1239-1245
13. Cugati S, Wang J J., Knudtson M D. et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007 114 520-524
14. Cugati S, Wang J J., Rochtchina E et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Archives of ophthalmology 2006 124 726-732
15. Brown G. Central retinal vein obstruction: diagnosis and management. In RD R ed Ophthalmology Annual. East Norwalk Appleton&Lange 1985 65-97
16. David R, Zangwill L, Badarna M et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica Journal international dophtalmologie International journal of ophthalmology 1988 197 69-74
17. Hayreh S S. Retinal vein occlusion. [Review] [64 refs]. Indian Journal of Ophthalmology 1994 42 109-132
18. Seitz R. Die Netzhautgefäße. Ferdinand Enke Verlag Stuttgart 1962 1ed 175
19. Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress on retinal microcirculation in humans. Investigative ophthalmology & visual science 2006 47 1113-1119
20. Wiek J, Schade M, Wiederholt M et al. Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution. The British journal of ophthalmology 1990 74 665-669
21. Boyd S R., Zachary I, Chakravarthy U et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of ophthalmology 2002 120 1644-1650
22. Stahl A, Buchwald A, Martin G et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina 2010; im Druck
23. Garci-Arumi J, Fonollosa A, Macia C et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye 2009 23 1066-1071
24. Inomata Y, Hirata A, Takahashi E et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 2004 15 877-879
25. Semenza G L. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 1994 8 863-884
26. Forsythe J A., Jiang B H., Iyer N V. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996 16 4604-4613
27. Chen J, Connor K M., Aderman C M. et al. Erythropoietin deficiency decreases vascular stability in mice. JClin Invest 2008 118 526-533
28. Chen J, Connor K M., Aderman C M. et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Investigative ophthalmology & visual science 2009 50 1329-1335
29. Junk A K., Mammis A, Savitz S I. et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002 99 10659-10664
30. Kooij M A., Groenendaal F van der, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008 59 22-33
31. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. The New England journal of medicine 2005 353 782-792 (Pubitemid 41215487)
32. Grasso G, Sfacteria A, Meli F et al. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 2007 1182 99-105
33. Gunnarson E, Song Y, Kowalewski J M. et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci U S A 2009 106 1602-1607
34. Friedman E A., LEsperance F A., Brown C D. et al. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int Suppl 2003(87) S57-S63
35. Chen J, Smith L E. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. JAAPOS 2008 12 221-222
36. Lagreze W A., Feltgen N, Bach M et al. Feasibility of intravitreal erythropoietin injections in humans. The British journal of ophthalmology 2009 93 (12) 1667-1671
37. Li W, Sinclair S H., Xu G T. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010 41 18-25
38. Brown D M., Campochiaro P A., Singh R P. et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 2010; online
39. Quinlan P M., Elman M J., Bhatt A K. et al. The natural course of central retinal vein occlusion. American journal of ophthalmology 1990 110 118-123
40. CVOS-Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. [comment][erratum appears in Arch Ophthalmol 1997;115 (10): 1275]. Comment in: Arch Ophthalmol 1998; 116 (2): 260 261; PMID: 9 488 292 Archives of ophthalmology 1997 115 486-491
41. rd J A., Adamis A P. et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of ophthalmology 2009 127 374-380
42. Haller J A., Bandello F, Belfort R Jr et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology 2010; online
43. Ip M S., Scott I U., VanVeldhuisen P C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Archives of ophthalmology 2009 127 1101-1114
44. McIntosh R L., Mohamed Q, Saw S M. et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007 114 835-854
45. Hayreh S S., Hayreh M S. Hemi-central retinal vein occulsion. Pathogenesis, clinical features, and natural history. Archives of ophthalmology 1980 98 1600-1609
46. Scott I U., Ip M S., Van Veldhuisen P C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Archives of ophthalmology 2009 127 1115-1128
47. Campochiaro P A., Heier J S., Feiner L et al. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 2010; online
48. Rogers S L., McIntosh R L., Lim L et al. Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology 2010 117 (6) 1094-1101 e5
49. Priglinger S G., Wolf A H., Kreutzer T C. et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007 27 1004-1012
50. McIntosh R L., Rogers S L., Lim L et al. Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology 2010; online
51. Hansen L L. Central retinal vein occlusion. In Joussen A Gardner T Kirchhof B eds Retinal Vascular Disease: Springer 2007
52. Dithmar S, Hansen L L., Holz F G. [Retinal vein occlusions]. Ophthalmologe 2003 100 561-577; quiz 578
53. Hayreh S S., Zimmerman M B., Beri M et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004 111 133-141
54. BVOS. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Archives of ophthalmology 1986 104 34-41
55. CVOS-Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.[comment]. Comment in: Ophthalmology 1996;103 (3): 352, discussion 353 354; PMID: 8 600 408, Comment in: Ophthalmology 1996; 103 (3): 352, discussion 353 354; PMID: 8 600 407, Comment in: Ophthalmology 1996; 103 (3): 352 354; PMID: 8 600 406. Ophthalmology 1995 102 1434-1444
56. Brckner R. Central retinal vein occlusion and its therapy. Ophthalmologica Journal international dophtalmologie International journal of ophthalmology 1955 129 325-326
57. Blankenship G W. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 1991 229 62-65
58. Penfold P L., Gyory J F., Hunyor A B. et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Australian and New Zealand journal of ophthalmology 1995 23 293-298
59. Greenberg P B., Martidis A, Rogers A H. et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. The British journal of ophthalmology 2002 86 247-248
60. Jonas J B., Kreissig I, Degenring R F. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2002 240 782-783
61. McAllister I L., Vijayasekaran S, Chen S D. et al. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. American journal of ophthalmology 2009 147 838-846, 846 e831-e832
62. Jonas J B., Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Progress in retinal and eye research 2005 24 587-611
63. Zhang X, Bao S, Lai D et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008 57 1026-1033
64. Edelman J L., Lutz D, Castro M R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005 80 249-258
65. Wang K, Wang Y, Gao L et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008 31 1541-1546
66. Kunikata H, Shimura M, Nakazawa T et al. Chemokines in aqueous humour before and after intravitreal triamcinolone acetonide in eyes with macular oedema associated with branch retinal vein occlusion. Acta Ophthalmol 2010; online
67. Wilson C A., Berkowitz B A., Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Archives of ophthalmology 1992 110 1155-1159
68. Jeanneteau F, Garabedian M J., Chao M V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci U S A 2008 105 4862-4867
69. Kube T, Sutter M, Trittler R et al. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2006 244 1385-1390
70. Bobbili R B., Mathai A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American journal of ophthalmology 2006 142 531; author reply 531 532
71. Cekic O, Bardak Y, Tig S U. et al. Hemodynamic response to intravitreal triamcinolone in eyes with macular edema: Intravitreal triamcinolone and ocular blood flow. Int Ophthalmol 2007 27 (5) 313-319
72. Chen S D., Sundaram V, Lochhead J et al. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. American journal of ophthalmology 2006 141 876-883
73. Degenring R F., Kamppeter B, Kreissig I et al. Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta ophthalmologica Scandinavica 2003 81 548-550
74. Flynn H W., Scott I U. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: its time for clinical trials. Archives of ophthalmology 2005 123 258-259
75. Goff M J., Jumper J M., Yang S S. et al. Intravitreal Triamcinolone Acetonide Treatment of Macular Edema Associated with Central Retinal Vein Occlusion. Retina 2006 26 896-901
76. Gregori N Z., Rosenfeld P J., Puliafito C A. et al. One-Year Safety and Efficacy of Intravitreal Triamcinolone Acetonide for the Management of Macular Edema Secondary to Central Retinal Vein Occlusion. Retina 2006 26 889-895
77. Hirano Y Jr, Sakurai E, Yoshida M et al. Comparative Study on Efficacy of a Combination Therapy of Triamcinolone Acetonide Administration with and without Vitrectomy for Macular Edema Associated with Branch Retinal Vein Occlusion. Ophthalmic research 2007 39 207-212
78. Ip M S., Gottlieb J L., Kahana A et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Archives of ophthalmology 2004 122 1131-1136
79. Jonas J B., Akkoyun I, Kamppeter B et al. Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. European journal of ophthalmology 2005 15 751-758 (Pubitemid 43074702)
80. Jonas J B., Akkoyun I, Kamppeter B et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005 19 65-71 (Pubitemid 40192642)
81. Krepler K, Ergun E, Sacu S et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta ophthalmologica Scandinavica 2005 83 600-604 (Pubitemid 41488636)
82. Moschos M M., Brouzas D, Loukianou E et al. Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study. Documenta ophthalmologica 2007 114 1-7
83. Oh J Y., Seo J H., Ahn J K. et al. Early versus Late Intravitreal Triamcinolone Acetonide for Macular Edema associated with Branch Retinal Vein Occlusion. Korean J Ophthalmol 2007 21 18-20
84. Patel P J., Zaheer I, Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye (Lond) 2008 22 (1) 60-64
85. Ramezani A, Entezari M, Moradian S et al. Intravitreal triamcinolone for acute central retinal vein occlusion, a randomized clinical trial. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2006 244 1601-1606
86. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. American journal of ophthalmology 2005 139 972-982
87. Byun Y J., Roh M I., Lee S C. et al. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2010 248 (7) 963-971
88. Guthoff R, Meigen T, Hennemann K et al. Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion A Matched-Pairs Analysis. Ophthalmologica Journal international dophtalmologie International journal of ophthalmology 2009 224 126-132
89. Cheng K C., Wu W C., Chen K J. Intravitreal triamcinolone acetonide vs. bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye 2009 23 2023-2033
90. Wu W C., Cheng K C., Wu H J. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009 23 2215-2222
91. Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Investigative ophthalmology & visual science 2008 49 2030-2038
92. Gan I M., Ugahary L C., Dissel J T. et al. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2005 243 1186-1189
93. Zhang Z G., Zhang L van, Jiang Q et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. JClin Invest 2000 106 829-838
94. Kaur C, Foulds W S., Ling E A. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008 2 879-889
95. Noma H, Funatsu H, Mimura T et al. Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. European journal of ophthalmology 2008 18 1017-1019
96. Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. American journal of ophthalmology 2005 140 256-261
97. Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2006 244 309-315
98. Kim K S., Chang H R., Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008 86 925-927
99. Shimura M, Yasuda K. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. The British journal of ophthalmology 2010 94 381-383
100. Shetty R, Pai S A., Vincent A et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Documenta ophthalmologica 2008 116 129-135
101. Bonini-Filho M, Costa R, Calucci D et al. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. American journal of ophthalmology 2009 147 1022-1030
102. Neubauer A, Kook D, Haritoglou C et al. Bevacizumab and retinal ischemia. Ophthalmology 2007 114 2096
103. Wroblewski J J., Wells 3 rd J A., Gonzales C R. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American journal of ophthalmology 2010 149 147-154
104. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Current opinion in ophthalmology 2008 19 234-238
105. Gregori N Z., Rattan G H., Rosenfeld P J. et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina 2009 29 913-925
106. Gutierrez J C., Barquet L A., Caminal J M. et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol 2008 2 787-791
107. Iturralde D, Spaide R F., Meyerle C B. et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006 26 279-284
108. Jaissle G B., Leitritz M, Gelisken F et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2009 247 27-33
109. Jaissle G B., Ziemssen F, Petermeier K et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. Bevacizumab zur Therapie des sekundren Makuladems nach vensen Gefverschlssen. Ophthalmologe 2006 103 471-475
110. Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. The British journal of ophthalmology 2008 92 518-522
111. Rabena M D., Pieramici D J., Castellarin A A. et al. Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Retina 2007 27 419-425
112. Schaal K B., Hoh A E., Scheuerle A et al. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion] Bevacizumab zur Therapie des Makuladems infolge venser retinaler Gefverschlsse. Ophthalmologe 2007 104 285-289
113. Kreutzer T C., Alge C S., Wolf A H. et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. The British journal of ophthalmology 2008 92 351-355
114. Stahl A, Agostini H, Hansen L L. et al. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2007 245 1429-1436
115. Tao Y, Hou J, Jiang Y R. et al. Intravitreal bevacizumab vs. triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2010 24 (5) 810-815
116. Wu L, Arevalo J F., Roca J A. et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008 28 212-219
117. Abegg M, Tappeiner C, Wolf-Schnurrbusch U et al. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008 8 18
118. Ach T, Hoeh A E., Schaal K B. et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2009 248 (2) 155-159
119. Ahmadi A A., Chuo J Y., Banashkevich A et al. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Canadian journal of ophthalmology 2009 44 154-159
120. Ahmadieh H, Moradian S, Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 2005 26 191-193
121. Algvere P V., Wendt G von, Gudmundsson J et al. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin). Acta Ophthalmol 2009; online
122. Chalam K V., Keshavamurthy R, Brar V S. Spectral domain OCT documented resolution of recalcitrant macular edema after intravitreal bevacizumab in branch retinal vein occlusion. European journal of ophthalmology 2008 18 831-833
123. Chung E J., Hong Y T., Lee S C. et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2008 246 1241-1247
124. Costa R A., Jorge R, Calucci D et al. Intravitreal Bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO Study. Retina 2007 27 141-149
125. Fish G E. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). Transactions of the American Ophthalmological Society 2008 106 276-300
126. Funk M, Kriechbaum K, Prager F et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investigative ophthalmology & visual science 2009 50 1025-1032
127. Hoeh A E., Ach T, Schaal K B. et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fr klinische und experimentelle Ophthalmologie 2009 247 1635-1641
128. Kondo M, Kondo N, Ito Y et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 2009 29 1242-1248
129. Matsumoto Y, Freund K B., Peiretti E et al. Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease. Retina 2007 27 426-431
130. Pai S A., Shetty R, Vijayan P B. et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. American journal of ophthalmology 2007 143 601-606
131. Pournaras J A., Nguyen C, Vaudaux J D. et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (avastin[r]): preliminary results. Klin Monatsbl fr Augenheilkd 2008 225 397-400
132. Rensch F, Jonas J B., Spandau U H. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009 87 (1) 77-81
133. Rosenfeld P J., Fung A E., Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005 36 336-339
134. Russo V, Barone A, Conte E et al. Bevacizumab Compared with Macular Laser Grid Photocoagulation for Cystoid Macular Edema in Branch Retinal Vein Occlusion. Retina 2009 29 (4) 511-515
135. Spandau U, Wickenhauser A, Rensch F et al. Intravitreal bevacizumab for branch retinal vein occlusion. Acta ophthalmologica Scandinavica 2007 85 118-119
136. Scott I U., Oden N L., Vanveldhuisen P C. et al. Standard Care vs Corticosteroid in Retinal Vein Occlusion Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated With Staked-on vs. Luer Cone Syringe Design. American journal of ophthalmology 2009 148 (5) 725-732 e7
137. Chu Y K., Chung E J., Kwon O W. et al. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye 2008 22 895-899
138. Beck R W., Edwards A R., Aiello L P. et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of ophthalmology 2009 127 245-251
139. Bashshur Z F., Maluf R N., Allam S et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Archives of ophthalmology 2004 122 1137-1140
140. Ladas I D., Karagiannis D A., Rouvas A A. et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009 29 313-318
141. Bakri S J., Ekdawi N S. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008 28 996-1001
142. Georgopoulos M, Polak K, Prager F et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). The British journal of ophthalmology 2009 93 457-462
143. Kocabora M S., Ozbilen K T., Serefoglu K. Intravitreal silicone oil droplets following pegaptanib injection. Acta Ophthalmol 2010 88 e44-e45
144. Ness T, Feltgen N, Agostini H et al. Toxic vitreitis outbreak after intravitreal injection. Retina 2010 30 332-338
145. Sato T, Emi K, Ikeda T et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010 117 (3) 512-516, 516 e12
146. Yamashiro K, Tsujikawa A, Miyamoto K et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010 30 485-490
147. Yenerel N M., Dinc U A., Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. JOcul Pharmacol Ther 2008 24 362-363
148. Regillo C D., Brown D M., Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American journal of ophthalmology 2008 145 239-248
149. Brown D M., Michels M, Kaiser P K. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009 116 57-65 e55
150. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England journal of medicine 2006 355 1432-1444
151. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine 2006 355 1419-1431
152. Chung Y R., Lee K, Cho E H. et al. Blood pressure changes after
153. Sakamoto A, Tsujikawa A, Ota M et al. Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion. Clin Experiment Ophthalmol 2009 37 208-216
154. Bates D O., Cui T G., Doughty J M. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002 62 4123-4131
155. Woolard J, Wang W Y., Bevan H S. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004 64 7822-7835
156. Perrin R M., Konopatskaya O, Qiu Y et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005 48 2422-2427
157. Magnussen A L., Rennel E S., Hua J et al. VEGF-A165b is cytoprotective and anti-angiogenic in the retina. Investigative ophthalmology & visual science 2010; online